Screener / SEC EDGAR /CIK 0001674416 /10-K filed Feb 12, 2026, compared with Feb 11, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

CRISPR Therapeutics AG CRSP

Compare with peers Embed
Earnings releases

Latest results release: Nov 2, 2026

8-K item 2.02, exhibit 99

What CRSP's management wrote with each quarter's results: the press release and, when the company files them, its prepared remarks or the call transcript. The call itself is not filed with SEC, so most quarters have the release only.

Read and search

Every release, in full · linked to sec.gov

Press release Nov 2, 2026 · EX-99.1

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2026

Open on SEC

Exhibit 99.1 CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results

– CASGEVY® revenue of $99 million in the third quarter of 2026, up 30% quarter- over-quarter and nearly six times the third quarter of 2025 –

– CASGEVY approved in the U.K. for children 5 years of age and older with severe SCD or TDT, and in the United Arab Emirates and Bahrain for children 2 years of age and older –

– FDA granted Regenerative Medicine Advanced Therapy (RMAT) designations to CTX310® for severe hypertriglyceridemia and elevated LDL-C –

– Phase 1b data for CTX310 in severe hypertriglyceridemia to be presented in a late-breaking oral presentation at AHA Scientific Sessions 2026; Phase 1 data for zugo-cel in systemic sclerosis to be presented at ACR Convergence 2026 –

– Completed enrollment in the Phase 2 clinical trial of CTX611 in patients undergoing total knee arthroplasty –

– Appointed Siva Sakhamuri, Ph.D., as Chief Technical Officer and A.J. Silver as Chief Financial Officer – ZUG, Switzerland and BOSTON, November 2, 2026–CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the third quarter ended September 30, 2026.

“The third quarter marked meaningful progress for CRISPR Therapeutics,” said Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutics. “CASGEVY is reaching more patients, including younger children following new approvals in the U.K. and the Middle East, and the FDA’s RMAT designations for CTX310 underscore its potential to address significant unmet needs in cardiovascular disease. With new clinical data from CTX310 and zugo-cel in the coming weeks and enrollment complete in our Phase 2 trial of CTX611, we are entering a pivotal period for our pipeline.” Recent Highlights and Outlook Hemoglobinopathies and CASGEVY® (exagamglogene autotemcel) CASGEVY, the world’s first approved CRISPR-based therapy, has been shown to reduce or eliminate vaso-occlusive crises (VOCs) in eligible patients with sickle cell disease (SCD) and transfusion requirements in eligible patients with transfusion-dependent beta thalassemia (TDT). CASGEVY is approved in 39 countries across North America, Europe, and the Middle East for eligible patients 12 years of age and older, with approvals for younger children in five of those countries.

CASGEVY generated third quarter 2026 revenue of $99 million, representing 30% growth quarter-over-quarter and nearly six times the revenue reported in the third quarter of 2025. Twice as many in the first nine months of 2026 as in all of 2025, and more than 750 patients have initiated treatment worldwide.

CASGEVY’s availability for younger patients continues to expand. In July, the FDA approved CASGEVY for children 2 years of age and older with SCD or TDT, making it the first genetic therapy for SCD and TDT approved for this age group, and multiple children have since initiated treatment in the U.S. The Kingdom of Saudi Arabia, the United Arab Emirates, and the Kingdom of Bahrain have also approved CASGEVY for children 2 years of age and older, and the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) approved CASGEVY for children 5 years of age and older with severe SCD or TDT.

Building on CASGEVY, CRISPR Therapeutics is advancing an in vivo hematopoietic stem cell editing approach that could extend gene editing to many more patients with SCD and TDT. Using lipid nanoparticle (LNP)-mediated delivery, the approach is designed to edit stem cells directly in the body, potentially simplifying treatment and broadening global access.

In VivoLiver Editing CRISPR Therapeutics continues to advance a diversified portfolio ofin vivogene editing programs leveraging its proprietary liver-directed LNP delivery platform. The Phase 1 clinical trial of CTX310®, targeting angiopoietin-related protein 3 (ANGPTL3) is ongoing.

CRISPR Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designations to CTX310 for the treatment of severe hypertriglyceridemia (sHTG) and for the treatment of patients with elevated LDL-C. RMAT designation provides the benefits of Fast Track and Breakthrough Therapy designations, including early interactions with the FDA and potential eligibility for priority review and accelerated approval.

In August, CRISPR Therapeutics presented Phase 1a durability data for CTX310 in a late-breaking session at the European Society of Cardiology (ESC) Congress 2026 and simultaneously published in The New England Journal of Medicine. A single course treatment of CTX310 produced deep and durable reductions in circulating ANGPTL3, triglycerides (TG), and low-density lipoprotein (LDL) that were sustained through one year of follow-up. At the highest dose, the mean reductions from baseline were 79% in ANGPTL3, 48% in triglycerides, and 53% in LDL-C in a mixed patient cohort with high triglycerides, high LDL-C, or both. CTX310 was well tolerated with no treatment-related serious adverse events.

Phase 1b data in patients with sHTG will be presented in a late-breaking oral presentation at the American Heart Association (AHA) Scientific Sessions 2026 on November 9, 2026, at 8:00 a.m. CT.

The Phase 1 clinical trial of CTX340™, targeting angiotensinogen (AGT), in patients with refractory hypertension is ongoing.

The Phase 1 clinical trial of CTX460™, targeting SERPINA1 for alpha-1 antitrypsin deficiency (AATD), is ongoing. CTX460 is the first investigational candidate from the Company’s SyNTase™ editing platform.

CTX321™, the Company’s next-generation LPA program, is progressing through IND/CTA-enabling studies.

siRNA-based Programs CRISPR Therapeutics’ small interfering RNA (siRNA)-based portfolio, developed in collaboration with Sirius Therapeutics, includes programs targeting cardiovascular and thromboembolic diseases. CRISPR Therapeutics has completed enrollment in the Phase 2 clinical trial of CTX611 (SRSD107), a long-acting siRNA therapeutic targeting Factor XI (FXI), in patients undergoing total knee arthroplasty (TKA), with an update expected in the second half of 2026. CTX611 has potential across a broad range of thromboembolic indications. CRISPR Therapeutics will lead global Phase 3 development, with Sirius Therapeutics overseeing development in greater China.

CRISPR Therapeutics has the option to nominate up to two additional siRNA targets, with an update expected in 2027.

Autoimmune Disease and Immuno-Oncology Zugocabtagene geleucel (zugo-cel; formerly CTX112™) continues to advance across both autoimmune disease and hematologic malignancies. In autoimmune disease, zugo-cel is being evaluated in three ongoing Phase 1 trials: a rheumatology basket including systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and inflammatory myositis (IM); a hematology basket in immune thrombocytopenic purpura (ITP) and warm autoimmune hemolytic anemia (wAIHA); and a trial in autoimmune neurologic diseases, including progressive multiple sclerosis (PMS), neuromyelitis optica spectrum disorder (NMOSD), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), N-methyl-D- aspartate receptor (NMDAR) and leucine-rich glioma-inactivated protein 1 (LGI1) autoimmune encephalitis (AIE), and stiff person syndrome (SPS). Enrollment is ongoing globally.

Phase 1 clinical data in patients with refractory SSc will be presented in a poster presentation at the American College of Rheumatology (ACR) Convergence 2026 on November 8 at 10:30 a.m. ET.

In immuno-oncology, the Phase 1/2 clinical trial of zugo-cel in B-cell malignancies is ongoing, with updates anticipated in the second half of 2026. A combination study evaluating zugo-cel with pirtobrutinib in aggressive B-cell lymphomas, under the Company’s existing collaboration with Lilly, is also ongoing. CRISPR Therapeutics is also advancing a proprietaryin vivoCAR-T platform with potential applications across autoimmune disease and oncology. The Company is pursuing two modalities, supported by an antibody-conjugated LNP delivery system targeting immune cells: a transient, re-dosable mRNA-based CAR-T and a non-viral, integrating CAR-T, for which the Company is evaluating multiple integration approaches. Both programs are in the IND/CTA-enabling phase, focused on a best-in-class profile.

The Company is developing CTX213™, a deviceless beta cell replacement candidate for Type 1 diabetes, consisting of unencapsulated precursor islet cells derived from edited induced pluripotent stem cells (iPSCs). CTX213 has demonstrated compelling preclinical efficacy through direct administration and is progressing toward the clinic.

Earlier today, CRISPR Therapeutics announced the appointment of Sivakesava Sakhamuri, Ph.D., as Chief Technical Officer, effective immediately. Dr. Sakhamuri brings more than 30 years of technical operations and quality leadership across biologics, vaccines, oligonucleotides, RNA therapeutics, and LNP delivery, most recently as Chief Technical Officer at Orna Therapeutics.

In October, CRISPR Therapeutics announced the appointment of A.J. Silver, the Company’s Senior Vice President of Finance, as Chief Financial Officer, effective October 19, 2026, succeeding Raju Prasad, Ph.D., who stepped down to pursue external opportunities.

The Company’s in vivo and cell therapy programs are supported by a wholly-owned GMP manufacturing facility in Framingham, Massachusetts. The facility provides end-to-end production capabilities, supports both clinical and future commercial supply, and enables an industry-leading cost of goods.

Cash Position: Cash, cash equivalents, and marketable securities were $2,276.6 million as of September 30, 2026, compared to $1,975.8 million as of December 31, 2025. The increase in cash was primarily driven by net proceeds of $585.4 million from the issuance of convertible senior notes in March 2026, offset by operating expenses.

R&D Expenses: R&D expenses were $71.9 million for the third quarter of 2026, compared to $58.9 million for the third quarter of 2025. The increase in R&D expense was primarily attributable to an increase in external research and development expenses and sublicense fees, offset by a decrease in employee- related costs.

Acquired In-Process R&D Expenses: Acquired in-process R&D expenses were $11.7 million for the third quarter of 2026. Acquired in-process R&D expenses for the third quarter of 2026 primarily consisted of a development milestone under the Sirius Agreement that was recognized in the third quarter of 2026. No acquired in-process R&D expenses were recognized during the third quarter of 2025.

G&A Expenses: General and administrative expenses were $17.9 million for the third quarter of 2026, compared to $16.9 million for the third quarter of 2025.

Collaboration Expense: Collaboration expense, net, was $41.3 million for the third quarter of 2026, compared to $57.1 million for the third quarter of 2025. The decrease was primarily attributable to an increase in the Company’s share of CASGEVY revenue.

Net Loss: Net loss was $111.4 million for the third quarter of 2026, compared to a net loss of $106.4 million for the third quarter of 2025. About CASGEVY® (exagamglogene autotemcel [exa-cel])

CASGEVY® is a non-viral,ex vivoCRISPR/Cas9 gene-edited cell therapy for eligible patients with sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT), in which a patient’s own hematopoietic stem and progenitor cells are edited at the erythroid specific enhancer region of the BCL11A gene. This edit results in the production of high levels of fetal hemoglobin (HbF; hemoglobin F) in red blood cells. HbF is the form of the oxygen-carrying hemoglobin that is naturally present during fetal development, which then switches to the adult form of hemoglobin after birth. CASGEVY has been shown to reduce or eliminate VOCs for patients with SCD and transfusion requirements for patients with TDT.

CASGEVY is approved for eligible SCD and TDT patients 12 years and older by multiple regulatory bodies around the world, and for younger children in select countries.

CRISPR Therapeutics and Vertex established a strategic research collaboration in 2015 to discover and develop therapies leveraging CRISPR/Cas9 technology to address the underlying genetic causes of human disease. CASGEVY is the first approved therapy to emerge from this collaboration. Under an amended agreement, Vertex leads global development, manufacturing, and commercialization of CASGEVY, and Vertex and CRISPR Therapeutics share profits and program costs on a 60/40 basis. Vertex is the manufacturer and exclusive license holder of CASGEVY.

CRISPR Therapeutics has established a proprietary lipid nanoparticle (LNP) delivery platform to enable gene editing in the liver using both CRISPR/Cas9 and its novel, proprietary SyNTase™ editing technology. The Company's in vivo portfolio includes three cardiovascular programs: CTX310, targeting angiopoietin-related protein 3 (ANGPTL3), in development for heterozygous and homozygous familial hypercholesterolemia, mixed dyslipidemias, and severe hypertriglyceridemia; CTX340, targeting angiotensinogen (AGT), in development for refractory hypertension; and CTX321, targeting LPA, in development for patients with elevated lipoprotein(a) [Lp(a)]. In addition, the Company's disclosed development candidates also include CTX460™, targeting SERPINA1 using SyNTase editing, for the treatment of alpha-1 antitrypsin deficiency (AATD).

CTX611 is a novel double-stranded, long-acting siRNA, designed to target the human coagulation factor XI, or FXI, messenger RNA and inhibit FXI protein expression. Through modulation of the intrinsic coagulation pathway, CTX611 is intended to provide anticoagulant and antithrombotic effects with a decreased risk of bleeding compared to other anti-thrombotics. Supported by clinical experience conducted by Sirius Therapeutics in two Phase 1 clinical trials, the Company and Sirius Therapeutics are developing CTX611 as a long-acting FXI inhibitor with the potential to support infrequent, including semi-annual, subcutaneous administration.

CRISPR Therapeutics and Sirius Therapeutics entered into a strategic collaboration in 2025 to develop and commercialize siRNA therapies for thromboembolic disorders and other serious diseases. The lead program, CTX611, is a long-acting siRNA targeting FXI, which the companies will co-develop on an equal cost-and-profit-sharing basis. CRISPR Therapeutics will lead commercialization in the U.S., while Sirius will lead commercialization in greater China. The collaboration also provides CRISPR Therapeutics with the option to license up to two additional siRNA programs.

Zugocabtagene geleucel (zugo-cel) is a wholly-owned, allogeneic chimeric antigen receptor (CAR) T cell therapy product candidate targeting Cluster of Differentiation 19 (CD19), in development for both autoimmune and immuno- oncology indications. The off-the-shelf therapy leverages CRISPR/Cas9 for targeted gene knockout and CAR insertion, enabling immune evasion and enhanced T effector cell potency, and is administered following a standard lymphodepletion regimen without the need for human leukocyte antigen (HLA) matching. In autoimmune disease, zugo-cel is being investigated in three ongoing basket trials. The rheumatology basket trial is enrolling adult patients with systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and inflammatory myositis (IM). The hematology basket trial is enrolling patients with immune thrombocytopenic purpura (ITP) and warm autoimmune hemolytic anemia (wAIHA). The neuroimmune basket trial is enrolling patients with progressive multiple sclerosis (PMS), neuromyelitis optica spectrum disorder (NMOSD), myelin oligodendrocyte glycoprotein antibody-associated Disease (MOGAD), N-methyl-D- aspartate receptor (NMDAR) and leucine-rich glioma-inactivated Protein 1 (LGI1) autoimmune encephalitis (AIE), and stiff person syndrome (SPS). In immuno- oncology, zugo-cel is being investigated in a trial in adult patients with relapsed or refractory B-cell malignancies.

CRISPR Therapeutics is a leading biopharmaceutical company focused on developing transformative gene-based medicines for serious human diseases. Founded over a decade ago as an early pioneer in CRISPR/Cas9 gene editing, the Company has evolved from a pioneering research-stage organization into an industry leader, marking a historic milestone with the approval of CASGEVY® (exagamglogene autotemcel [exa-cel]), the world’s first CRISPR-based therapy, for eligible patients with sickle cell disease and transfusion-dependent beta thalassemia. Today, CRISPR Therapeutics is advancing a broad, diversified pipeline spanning hemoglobinopathies, cardiovascular disease, autoimmune disease, oncology, regenerative medicine and rare diseases. The Company is also expanding its gene editing toolkit through SyNTase™ editing, its novel, proprietary platform designed to enable precise, efficient, and scalable gene correction. To accelerate its impact, CRISPR Therapeutics has established strategic collaborations with leading biopharmaceutical partners, including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California. To learn more, visit www.crisprtx.com.

CRISPR THERAPEUTICS® standard character mark and design logo, CTX112™, CTX213™, CTX310®, CTX321™, CTX340™, CTX460™, CTX611™ and SyNTase™ are trademarks and registered trademarks of CRISPR Therapeutics AG. CASGEVY® and the CASGEVY logo are registered trademarks of Vertex Pharmaceuticals Incorporated. All other trademarks and registered trademarks are the property of their respective owners.

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements made by Dr. Kulkarni in this press release, as well as regarding any or all of the following: (i) CRISPR Therapeutics preclinical studies, clinical trials and pipeline products and programs, including, without limitation, manufacturing capabilities, status of such studies and trials, potential expansion into new indications and expectations regarding data, safety and efficacy generally; (ii) data included in this press release, as well as the ability to use data from ongoing and planned studies and clinical trials for the design and initiation of further studies and clinical trials; (iii) CRISPR Therapeutics strategy, goals, anticipated financial performance and the sufficiency of its cash resources; (iv) plans and expectations for the commercialization of and anticipated benefits of CASGEVY, including anticipated patient access to CASGEVY; (v) regulatory submissions and authorizations, including timelines for and expectations regarding regulatory agency decisions; (vi) the expected benefits of its collaborations; and (vii) the therapeutic value, development, and commercial potential of gene editing technologies and therapies, including CRISPR/Cas9 and SyNTase, as well as other technologies. Risks that contribute to the uncertain nature of the forward-looking statements include, without limitation, the risks and uncertainties discussed under the heading “Risk Factors” in its most recent annual report on Form 10-K and in any other subsequent filings made by CRISPR Therapeutics with the U.S. Securities and Exchange Commission. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. We disclaim any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.

This press release also contains information regarding our industry, our business and the markets for certain of our product candidates, including data regarding the estimated size of those markets, and the incidence and prevalence of certain medical conditions. Unless otherwise expressly stated, we obtained this industry, business, market and other data from market research firms and other third parties, including medical publications, government data and similar sources. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. This press release discusses investigational therapies and is not intended to convey conclusions about efficacy or safety as to those investigational therapies or uses of such investigational therapies. There is no guarantee that any investigational therapy will successfully complete clinical development or gain approval from applicable regulatory authorities.

[email protected] CRISPR Therapeutics AG Condensed Consolidated Statements of Operations (Unaudited, In thousands except share data and per share data)

CRISPR Therapeutics AG Condensed Consolidated Balance Sheets Data (Unaudited, in thousands)

Full text with the tables
                                                                    Exhibit 99.1
  CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2026   
                               Financial Results                                
                                                                                
– CASGEVY® revenue of $99 million in the third quarter of 2026, up 30% quarter- 
         over-quarter and nearly six times the third quarter of 2025 –          
                                                                                
– CASGEVY approved in the U.K. for children 5 years of age and older with severe
SCD or TDT, and in the United Arab Emirates and Bahrain for children 2 years of 
                                age and older –                                 
                                                                                
  – FDA granted Regenerative Medicine Advanced Therapy (RMAT) designations to   
          CTX310® for severe hypertriglyceridemia and elevated LDL-C –          
                                                                                
 – Phase 1b data for CTX310 in severe hypertriglyceridemia to be presented in a 
 late-breaking oral presentation at AHA Scientific Sessions 2026; Phase 1 data  
  for zugo-cel in systemic sclerosis to be presented at ACR Convergence 2026 –  
                                                                                
   – Completed enrollment in the Phase 2 clinical trial of CTX611 in patients   
                      undergoing total knee arthroplasty –                      
                                                                                
– Appointed Siva Sakhamuri, Ph.D., as Chief Technical Officer and A.J. Silver as
                           Chief Financial Officer –                            
ZUG, Switzerland and BOSTON, November 2, 2026–CRISPR Therapeutics (Nasdaq: CRSP)
today reported financial results for the third quarter ended September 30, 2026.
                                                                                
“The third quarter marked meaningful progress for CRISPR Therapeutics,” said    
Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRISPR         
Therapeutics. “CASGEVY is reaching more patients, including younger children    
following new approvals in the U.K. and the Middle East, and the FDA’s RMAT     
designations for CTX310 underscore its potential to address significant unmet   
needs in cardiovascular disease. With new clinical data from CTX310 and zugo-cel
in the coming weeks and enrollment complete in our Phase 2 trial of CTX611, we  
are entering a pivotal period for our pipeline.”                                
Recent Highlights and Outlook
Hemoglobinopathies and CASGEVY® (exagamglogene autotemcel)                      
CASGEVY, the world’s first approved CRISPR-based therapy, has been shown to
reduce or eliminate vaso-occlusive crises (VOCs) in eligible patients with
sickle cell disease (SCD) and transfusion requirements in eligible patients with
transfusion-dependent beta thalassemia (TDT). CASGEVY is approved in 39
countries across North America, Europe, and the Middle East for eligible
patients 12 years of age and older, with approvals for younger children in five
of those countries.

CASGEVY generated third quarter 2026 revenue of $99 million, representing 30%
growth quarter-over-quarter and nearly six times the revenue reported in the
third quarter of 2025. Twice as many in the first nine months of 2026 as in all
of 2025, and more than 750 patients have initiated treatment worldwide.

CASGEVY’s availability for younger patients continues to expand. In July, the
FDA approved CASGEVY for children 2 years of age and older with SCD or TDT,
making it the first genetic therapy for SCD and TDT approved for this age group,
and multiple children have since initiated treatment in the U.S. The Kingdom of
Saudi Arabia, the United Arab Emirates, and the Kingdom of Bahrain have also
approved CASGEVY for children 2 years of age and older, and the U.K. Medicines
and Healthcare products Regulatory Agency (MHRA) approved CASGEVY for children 5
years of age and older with severe SCD or TDT.

Building on CASGEVY, CRISPR Therapeutics is advancing an in vivo hematopoietic
stem cell editing approach that could extend gene editing to many more patients
with SCD and TDT. Using lipid nanoparticle (LNP)-mediated delivery, the approach
is designed to edit stem cells directly in the body, potentially simplifying
treatment and broadening global access.

In VivoLiver Editing
CRISPR Therapeutics continues to advance a diversified portfolio ofin vivogene  
editing programs leveraging its proprietary liver-directed LNP delivery         
platform.                                                                       
The Phase 1 clinical trial of CTX310®, targeting angiopoietin-related protein 3
(ANGPTL3) is ongoing.

CRISPR Therapeutics today announced that the U.S. Food and Drug Administration
(FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designations to
CTX310 for the treatment of severe hypertriglyceridemia (sHTG) and for the
treatment of patients with elevated LDL-C. RMAT designation provides the
benefits of Fast Track and Breakthrough Therapy designations, including early
interactions with the FDA and potential eligibility for priority review and
accelerated approval.

In August, CRISPR Therapeutics presented Phase 1a durability data for CTX310 in
a late-breaking session at the European Society of Cardiology (ESC) Congress
2026 and simultaneously published in The New England Journal of Medicine. A
single course treatment of CTX310 produced deep and durable reductions in
circulating ANGPTL3, triglycerides (TG), and low-density lipoprotein (LDL) that
were sustained through one year of follow-up. At the highest dose, the mean
reductions from baseline were 79% in ANGPTL3, 48% in triglycerides, and 53% in
LDL-C in a mixed patient cohort with high triglycerides, high LDL-C, or both.
CTX310 was well tolerated with no treatment-related serious adverse events.

Phase 1b data in patients with sHTG will be presented in a late-breaking oral
presentation at the American Heart Association (AHA) Scientific Sessions 2026 on
November 9, 2026, at 8:00 a.m. CT.

The Phase 1 clinical trial of CTX340™, targeting angiotensinogen (AGT), in
patients with refractory hypertension is ongoing.

The Phase 1 clinical trial of CTX460™, targeting SERPINA1 for alpha-1
antitrypsin deficiency (AATD), is ongoing. CTX460 is the first investigational
candidate from the Company’s SyNTase™ editing platform.

CTX321™, the Company’s next-generation LPA program, is progressing through
IND/CTA-enabling studies.

siRNA-based Programs
CRISPR Therapeutics’ small interfering RNA (siRNA)-based portfolio, developed in
collaboration with Sirius Therapeutics, includes programs targeting             
cardiovascular and thromboembolic diseases.                                     
CRISPR Therapeutics has completed enrollment in the Phase 2 clinical trial of
CTX611 (SRSD107), a long-acting siRNA therapeutic targeting Factor XI (FXI), in
patients undergoing total knee arthroplasty (TKA), with an update expected in
the second half of 2026. CTX611 has potential across a broad range of
thromboembolic indications. CRISPR Therapeutics will lead global Phase 3
development, with Sirius Therapeutics overseeing development in greater China.

CRISPR Therapeutics has the option to nominate up to two additional siRNA
targets, with an update expected in 2027.

Autoimmune Disease and Immuno-Oncology
Zugocabtagene geleucel (zugo-cel; formerly CTX112™) continues to advance across 
both autoimmune disease and hematologic malignancies.                           
In autoimmune disease, zugo-cel is being evaluated in three ongoing Phase 1
trials: a rheumatology basket including systemic lupus erythematosus (SLE),
systemic sclerosis (SSc), and inflammatory myositis (IM); a hematology basket in
immune thrombocytopenic purpura (ITP) and warm autoimmune hemolytic anemia
(wAIHA); and a trial in autoimmune neurologic diseases, including progressive
multiple sclerosis (PMS), neuromyelitis optica spectrum disorder (NMOSD), myelin
oligodendrocyte glycoprotein antibody-associated disease (MOGAD), N-methyl-D-
aspartate receptor (NMDAR) and leucine-rich glioma-inactivated protein 1 (LGI1)
autoimmune encephalitis (AIE), and stiff person syndrome (SPS). Enrollment is
ongoing globally.

Phase 1 clinical data in patients with refractory SSc will be presented in a
poster presentation at the American College of Rheumatology (ACR) Convergence
2026 on November 8 at 10:30 a.m. ET.

In immuno-oncology, the Phase 1/2 clinical trial of zugo-cel in B-cell
malignancies is ongoing, with updates anticipated in the second half of 2026. A
combination study evaluating zugo-cel with pirtobrutinib in aggressive B-cell
lymphomas, under the Company’s existing collaboration with Lilly, is also
ongoing.
CRISPR Therapeutics is also advancing a proprietaryin vivoCAR-T platform with   
potential applications across autoimmune disease and oncology.                  
The Company is pursuing two modalities, supported by an antibody-conjugated LNP
delivery system targeting immune cells: a transient, re-dosable mRNA-based CAR-T
and a non-viral, integrating CAR-T, for which the Company is evaluating multiple
integration approaches. Both programs are in the IND/CTA-enabling phase, focused
on a best-in-class profile.

Regenerative Medicine

The Company is developing CTX213™, a deviceless beta cell replacement candidate
for Type 1 diabetes, consisting of unencapsulated precursor islet cells derived
from edited induced pluripotent stem cells (iPSCs). CTX213 has demonstrated
compelling preclinical efficacy through direct administration and is progressing
toward the clinic.

Other Corporate Matters

Earlier today, CRISPR Therapeutics announced the appointment of Sivakesava
Sakhamuri, Ph.D., as Chief Technical Officer, effective immediately. Dr.
Sakhamuri brings more than 30 years of technical operations and quality
leadership across biologics, vaccines, oligonucleotides, RNA therapeutics, and
LNP delivery, most recently as Chief Technical Officer at Orna Therapeutics.

In October, CRISPR Therapeutics announced the appointment of A.J. Silver, the
Company’s Senior Vice President of Finance, as Chief Financial Officer,
effective October 19, 2026, succeeding Raju Prasad, Ph.D., who stepped down to
pursue external opportunities.

The Company’s in vivo and cell therapy programs are supported by a wholly-owned
GMP manufacturing facility in Framingham, Massachusetts. The facility provides
end-to-end production capabilities, supports both clinical and future commercial
supply, and enables an industry-leading cost of goods.

Third Quarter 2026 Financial Results

Cash Position: Cash, cash equivalents, and marketable securities were $2,276.6
million as of September 30, 2026, compared to $1,975.8 million as of December
31, 2025. The increase in cash was primarily driven by net proceeds of $585.4
million from the issuance of convertible senior notes in March 2026, offset by
operating expenses.

R&D Expenses: R&D expenses were $71.9 million for the third quarter of 2026,
compared to $58.9 million for the third quarter of 2025. The increase in R&D
expense was primarily attributable to an increase in external research and
development expenses and sublicense fees, offset by a decrease in employee-
related costs.

Acquired In-Process R&D Expenses: Acquired in-process R&D expenses were $11.7
million for the third quarter of 2026. Acquired in-process R&D expenses for the
third quarter of 2026 primarily consisted of a development milestone under the
Sirius Agreement that was recognized in the third quarter of 2026. No acquired
in-process R&D expenses were recognized during the third quarter of 2025.

G&A Expenses: General and administrative expenses were $17.9 million for the
third quarter of 2026, compared to $16.9 million for the third quarter of 2025.

Collaboration Expense: Collaboration expense, net, was $41.3 million for the
third quarter of 2026, compared to $57.1 million for the third quarter of 2025.
The decrease was primarily attributable to an increase in the Company’s share of
CASGEVY revenue.

Net Loss: Net loss was $111.4 million for the third quarter of 2026, compared to
a net loss of $106.4 million for the third quarter of 2025.
About CASGEVY® (exagamglogene autotemcel [exa-cel])                             
                                                                                
CASGEVY® is a non-viral,ex vivoCRISPR/Cas9 gene-edited cell therapy for eligible
patients with sickle cell disease (SCD) or transfusion-dependent beta           
thalassemia (TDT), in which a patient’s own hematopoietic stem and progenitor   
cells are edited at the erythroid specific enhancer region of the BCL11A gene.  
This edit results in the production of high levels of fetal hemoglobin (HbF;    
hemoglobin F) in red blood cells. HbF is the form of the oxygen-carrying        
hemoglobin that is naturally present during fetal development, which then       
switches to the adult form of hemoglobin after birth. CASGEVY has been shown to 
reduce or eliminate VOCs for patients with SCD and transfusion requirements for 
patients with TDT.                                                              
                                                                                
CASGEVY is approved for eligible SCD and TDT patients 12 years and older by     
multiple regulatory bodies around the world, and for younger children in select 
countries.                                                                      
                                                                                
About the CRISPR Therapeutics - Vertex Collaboration for CASGEVY                
                                                                                
CRISPR Therapeutics and Vertex established a strategic research collaboration in
2015 to discover and develop therapies leveraging CRISPR/Cas9 technology to     
address the underlying genetic causes of human disease. CASGEVY is the first    
approved therapy to emerge from this collaboration. Under an amended agreement, 
Vertex leads global development, manufacturing, and commercialization of        
CASGEVY, and Vertex and CRISPR Therapeutics share profits and program costs on a
60/40 basis. Vertex is the manufacturer and exclusive license holder of CASGEVY.
                                                                                
AboutIn VivoLiver Editing Programs                                              
                                                                                
CRISPR Therapeutics has established a proprietary lipid nanoparticle (LNP)      
delivery platform to enable gene editing in the liver using both CRISPR/Cas9 and
its novel, proprietary SyNTase™ editing technology. The Company's in vivo       
portfolio includes three cardiovascular programs: CTX310, targeting             
angiopoietin-related protein 3 (ANGPTL3), in development for heterozygous and   
homozygous familial hypercholesterolemia, mixed dyslipidemias, and severe       
hypertriglyceridemia; CTX340, targeting angiotensinogen (AGT), in development   
for refractory hypertension; and CTX321, targeting LPA, in development for      
patients with elevated lipoprotein(a) [Lp(a)]. In addition, the Company's       
disclosed development candidates also include CTX460™, targeting SERPINA1 using 
SyNTase editing, for the treatment of alpha-1 antitrypsin deficiency (AATD).    
                                                                                
About CTX611 (SRSD107)                                                          
                                                                                
CTX611 is a novel double-stranded, long-acting siRNA, designed to target the    
human coagulation factor XI, or FXI, messenger RNA and inhibit FXI protein      
expression. Through modulation of the intrinsic coagulation pathway, CTX611 is  
intended to provide anticoagulant and antithrombotic effects with a decreased   
risk of bleeding compared to other anti-thrombotics. Supported by clinical      
experience conducted by Sirius Therapeutics in two Phase 1 clinical trials, the 
Company and Sirius Therapeutics are developing CTX611 as a long-acting FXI      
inhibitor with the potential to support infrequent, including semi-annual,      
subcutaneous administration.                                                    
                                                                                
About the CRISPR Therapeutics - Sirius Therapeutics Collaboration for siRNA     
                                                                                
CRISPR Therapeutics and Sirius Therapeutics entered into a strategic            
collaboration in 2025 to develop and commercialize siRNA therapies for          
thromboembolic disorders and other serious diseases. The lead program, CTX611,  
is a long-acting siRNA targeting FXI, which the companies will co-develop on an 
equal cost-and-profit-sharing basis. CRISPR Therapeutics will lead              
commercialization in the U.S., while Sirius will lead commercialization in      
greater China. The collaboration also provides CRISPR Therapeutics with the     
option to license up to two additional siRNA programs.                          
                                                                                
About Zugocabtagene Geleucel (zugo-cel; formerly CTX112)                        
                                                                                
Zugocabtagene geleucel (zugo-cel) is a wholly-owned, allogeneic chimeric antigen
receptor (CAR) T cell therapy product candidate targeting Cluster of            
Differentiation 19 (CD19), in development for both autoimmune and immuno-       
oncology indications. The off-the-shelf therapy leverages CRISPR/Cas9 for       
targeted gene knockout and CAR insertion, enabling immune evasion and enhanced T
effector cell potency, and is administered following a standard lymphodepletion 
regimen without the need for human leukocyte antigen (HLA) matching. In         
autoimmune disease, zugo-cel is being investigated in three ongoing basket      
trials. The rheumatology basket trial is enrolling adult patients with systemic 
lupus erythematosus (SLE), systemic sclerosis (SSc), and inflammatory myositis  
(IM). The hematology basket trial is enrolling patients with immune             
thrombocytopenic purpura (ITP) and warm autoimmune hemolytic anemia (wAIHA). The
neuroimmune basket trial is enrolling patients with progressive multiple        
sclerosis (PMS), neuromyelitis optica spectrum disorder (NMOSD), myelin         
oligodendrocyte glycoprotein antibody-associated Disease (MOGAD), N-methyl-D-   
aspartate receptor (NMDAR) and leucine-rich glioma-inactivated Protein 1 (LGI1) 
autoimmune encephalitis (AIE), and stiff person syndrome (SPS). In immuno-      
oncology, zugo-cel is being investigated in a trial in adult patients with      
relapsed or refractory B-cell malignancies.                                     
                                                                                
About CRISPR Therapeutics                                                       
                                                                                
CRISPR Therapeutics is a leading biopharmaceutical company focused on developing
transformative gene-based medicines for serious human diseases. Founded over a  
decade ago as an early pioneer in CRISPR/Cas9 gene editing, the Company has     
evolved from a pioneering research-stage organization into an industry leader,  
marking a historic milestone with the approval of CASGEVY® (exagamglogene       
autotemcel [exa-cel]), the world’s first CRISPR-based therapy, for eligible     
patients with sickle cell disease and transfusion-dependent beta thalassemia.   
Today, CRISPR Therapeutics is advancing a broad, diversified pipeline spanning  
hemoglobinopathies, cardiovascular disease, autoimmune disease, oncology,       
regenerative medicine and rare diseases. The Company is also expanding its gene 
editing toolkit through SyNTase™ editing, its novel, proprietary platform       
designed to enable precise, efficient, and scalable gene correction. To         
accelerate its impact, CRISPR Therapeutics has established strategic            
collaborations with leading biopharmaceutical partners, including Vertex        
Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland,   
with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D       
operations based in Boston, Massachusetts and San Francisco, California. To     
learn more, visit www.crisprtx.com.                                             
                                                                                
CRISPR THERAPEUTICS® standard character mark and design logo, CTX112™, CTX213™, 
CTX310®, CTX321™, CTX340™, CTX460™, CTX611™ and SyNTase™ are trademarks and     
registered trademarks of CRISPR Therapeutics AG. CASGEVY® and the CASGEVY logo  
are registered trademarks of Vertex Pharmaceuticals Incorporated. All other     
trademarks and registered trademarks are the property of their respective       
owners.                                                                         
                                                                                
CRISPR Special Note Regarding Forward-Looking Statements                        
                                                                                
Statements contained in this press release regarding matters that are not       
historical facts are “forward-looking statements” within the meaning of the     
Private Securities Litigation Reform Act of 1995. Because such statements are   
subject to risks and uncertainties, actual results may differ materially from   
those expressed or implied by such forward-looking statements. Such statements  
include, but are not limited to, statements made by Dr. Kulkarni in this press  
release, as well as regarding any or all of the following: (i) CRISPR           
Therapeutics preclinical studies, clinical trials and pipeline products and     
programs, including, without limitation, manufacturing capabilities, status of  
such studies and trials, potential expansion into new indications and           
expectations regarding data, safety and efficacy generally; (ii) data included  
in this press release, as well as the ability to use data from ongoing and      
planned studies and clinical trials for the design and initiation of further    
studies and clinical trials; (iii) CRISPR Therapeutics strategy, goals,         
anticipated financial performance and the sufficiency of its cash resources;    
(iv) plans and expectations for the commercialization of and anticipated        
benefits of CASGEVY, including anticipated patient access to CASGEVY; (v)       
regulatory submissions and authorizations, including timelines for and          
expectations regarding regulatory agency decisions; (vi) the expected benefits  
of its collaborations; and (vii) the therapeutic value, development, and        
commercial potential of gene editing technologies and therapies, including      
CRISPR/Cas9 and SyNTase, as well as other technologies. Risks that contribute to
the uncertain nature of the forward-looking statements include, without         
limitation, the risks and uncertainties discussed under the heading “Risk       
Factors” in its most recent annual report on Form 10-K and in any other         
subsequent filings made by CRISPR Therapeutics with the U.S. Securities and     
Exchange Commission. Existing and prospective investors are cautioned not to    
place undue reliance on these forward-looking statements, which speak only as of
the date they are made. We disclaim any obligation or undertaking to update or  
revise any forward-looking statements contained in this press release, other    
than to the extent required by law.                                             
                                                                                
This press release also contains information regarding our industry, our        
business and the markets for certain of our product candidates, including data  
regarding the estimated size of those markets, and the incidence and prevalence 
of certain medical conditions. Unless otherwise expressly stated, we obtained   
this industry, business, market and other data from market research firms and   
other third parties, including medical publications, government data and similar
sources. Information that is based on estimates, forecasts, projections, market 
research or similar methodologies is inherently subject to uncertainties and    
actual events or circumstances may differ materially from events and            
circumstances reflected in this information. This press release discusses       
investigational therapies and is not intended to convey conclusions about       
efficacy or safety as to those investigational therapies or uses of such        
investigational therapies. There is no guarantee that any investigational       
therapy will successfully complete clinical development or gain approval from   
applicable regulatory authorities.                                              
                                                                                
Investor Contact:                                                               
                                                                                
+1-617-307-7503                                                                 
                                                                                
[email protected]                                                                 
                                                                                
Media Contact:                                                                  
                                                                                
+1-617-315-4493                                                                 
                                                                                
[email protected]                                                              
CRISPR Therapeutics AG Condensed Consolidated Statements of Operations
(Unaudited, In thousands except share data and per share data)
                                                                                
          Three                               Nine                              
          Mont…                               Mont…                             
          Ended                               Ended                             
          Sept…                               Sept…                             
          30,                                 30,                               
  Rev…    2026               2025             2026              2025            
 ────────────────────────────────────────────────────────────────────────────── 
  Col…    $      12,3…       $        —       $      23,…       $         —     
  rev…                                                                          
  Gra…             346              889               985             2,646     
  rev…                                                                          
  Tot…           12,6…              889              24,…             2,646     
  rev…                                                                          
  Ope…                                                                          
  exp…                                                                          
  Res…                                                                          
  and            71,8…             58,…              207…             201,…     
  dev…                                                                          
  Acq…                                                                          
  in-…                                                                          
  res…           11,6…                —              14,…             96,2…     
  and                                                                           
  dev…                                                                          
  Gen…                                                                          
  and            17,8…             16,…              52,…             55,1…     
  adm…                                                                          
  Col…                                                                          
  exp…           41,2…             57,…              127…             159,…     
  net                                                                           
  Tot…                                                                          
  ope…           142,…             132…              401…             512,…     
  exp…                                                                          
  Loss                                                                          
  from           (130…  )          (13…  )           (37…  )          (509…  )  
  ope…                                                                          
  Tot…                                                                          
  oth…           18,6…             26,…              53,…             61,8…     
  inc…                                                                          
  net                                                                           
  Net                                                                           
  loss                                                                          
  bef…           (111…  )          (10…  )           (32…  )          (447…  )  
  inc…                                                                          
  tax…                                                                          
  Pro…                                                                          
  for              (74  )          (619  )           (1,…  )          (3,0…  )  
  inc…                                                                          
  tax…                                                                          
  Net            (111…  )          (10…  )           (32…  )          (450…  )  
  loss                                                                          
  For…                                                                          
  cur…               2              (28  )            (20  )             94     
  tra…                                                                          
  adj…                                                                          
  Unr…                                                                          
  (lo…                                                                          
  gain           (9,4…  )           973              (18…  )          3,052     
  on                                                                            
  mar…                                                                          
  sec…                                                                          
  Com…    $      (120…  )    $     (10…  )    $      (34…  )    $     (447…  )  
  loss                                                                          
  Net                                                                           
  loss                                                                          
  per                                                                           
  com…    $      (1.15  )    $     (1.…  )    $      (3.…  )    $     (5.12  )  
  sha…                                                                          
  —                                                                             
  bas…                                                                          
  Bas…                                                                          
  wei…                                                                          
  com…           96,7…             91,…              96,…             88,1…     
  sha…                                                                          
  out…                                                                          
  Net                                                                           
  loss                                                                          
  per                                                                           
  com…    $      (1.15  )    $     (1.…  )    $      (3.…  )    $     (5.12  )  
  sha…                                                                          
  —                                                                             
  dil…                                                                          
  Dil…                                                                          
  wei…                                                                          
  com…           96,7…             91,…              96,…             88,1…     
  sha…                                                                          
  out…                                                                          
                                                                                
CRISPR Therapeutics AG Condensed Consolidated Balance Sheets Data (Unaudited, in
thousands)
                                                                                
                             As of  September 30, 2026       December 31, 2025  
 ────────────────────────────────────────────────────────────────────────────── 
  Cash and cash              $                 192,027    $            347,559  
  equivalents                                                                   
  Marketable securities                      2,080,521               1,628,269  
  Marketable securities -                        4,021                       —  
  non-current                                                                   
  Working capital                            2,144,117               1,836,551  
  Total assets                               2,556,412               2,265,243  
  Total shareholders'                        1,648,068               1,921,813  
  equity                                                                        
                                                                                

Sources

The 8-K item 2.02 filings (SEC EDGAR) and their EX-99 exhibits: the results release and, when filed, prepared remarks or the call transcript.

Also

Said vs did: the targets in these releases against what was then reported. Filings: every filing.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/CRSP/export.csv") into a cell.

Next:Presentations
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.